Guinea: The Ebola Vaccine - Seven Things to Understand About rVSV-ZEBOV

[Ebola Deeply] A trial of the rVSV-ZEBOV Ebola vaccine among 7,651 individuals in Guinea has been found to have a protection rate of 100 percent. The vaccine was developed by Merck, the Wellcome Trust and the governments of Norway and Canada, in conjunction with MSF and the London School of Hygiene and Tropical Medicine. Public health experts are calling for the vaccine to be rolled out immediately.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news